Volume 19, Issue 2 pp. 205-210
Original Article

Inpatient management of gout in a New Zealand hospital: a retrospective audit

Nicholas J. Kennedy

Corresponding Author

Nicholas J. Kennedy

Wellington Regional Rheumatology Unit, Hutt Valley DHB, Lower Hutt, New Zealand

Correspondence: Dr Nicholas Kennedy, Department of Immunology and Rheumatology, Christchurch hospital, Private bag 4710, Christchurch 8140, New Zealand.

Email: [email protected]

Search for more papers by this author
Paul J. Healy

Paul J. Healy

Wellington Regional Rheumatology Unit, Hutt Valley DHB, Lower Hutt, New Zealand

Search for more papers by this author
Andrew A. Harrison

Andrew A. Harrison

Wellington Regional Rheumatology Unit, Hutt Valley DHB, Lower Hutt, New Zealand

Search for more papers by this author
First published: 15 April 2015
Citations: 11

Abstract

Aim

To review inpatient management of acute gout in a New Zealand hospital.

Methods

A retrospective file review of all acute episodes of gout at Hutt Hospital, Wellington, New Zealand over a 1 year period.

Results

In the course of a year, there were 90 admissions for, or complicated by, acute gout. In 31 cases, gout was the primary diagnosis. Median length of stay was 5 days and readmissions were common. The majority of patients (87%) were known to have gout before admission, yet only 50% of these patients were on uric acid lowering treatment. Serum urate was measured in only 60% of patients with a mean level of 0.471 mmol/L. Treatment for the acute attack was evenly split between monotherapy (49%) and polytherapy (49%). Treatment modalities used were: prednisone (61%), non-steroidal anti-inflammatories (40%), colchicine (40%), adrenocorticotrophic hormone (ACTH) (15%) and intrarticular steroids (7%). Patients were generally treated in a timely manner with few patients experiencing delays. Patients seen by the Rheumatology Department were more likely to receive polytherapy, be treated with intra-articular steroids or ACTH and to start allopurinol. The ‘treat-to-target’ approach to the management of elevated serum urate was mentioned in only 9% of cases.

Conclusion

There was considerable variability in the investigation and management of acute gout, with significant deviation from published protocols. The ‘treat-to-target’ approach to the management of elevated urate has not yet been widely adopted by the physicians in this New Zealand hospital.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.